"Identifying an association between AMD and valvular heart disease may provide important insights to the pathogenesis of AMD, may serve as a biomarker for these diseases, and may potentially assist in ...

Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Knowns and the Unknowns Sunir Garg, MD, considers what he has learned in the years since the first anti-VEGF therapies became ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...

Artificial intelligence (AI) is on the cusp of transforming how age-related macular degeneration (AMD) is diagnosed, monitored, and treated both in the medical office and at home, specialists say.

EURETINA 2024 In Gene Therapy for RP, LCA, the Earlier, the Better A real-world study of an FDA-approved gene therapy for inherited retinal disease shows younger patients gain more visual improvements ...

Optometrists (healthcare providers who offer standard eye care) can diagnose wet age-related macular degeneration (AMD) but can't treat it. Therapies for wet AMD are primarily led by ophthalmologists ...

GLP-1 receptor agonists are being linked to a long list of benefits besides weight loss and diabetes, as evidence suggests they can lower the risk of conditions ranging from cancer and addiction to ...

Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...

– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...